These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 11155742)

  • 1. Frequency and characterization of platelet-specific antibodies in patients who received multiple platelet transfusions.
    Lo SC; Lin DT; Lin SW; Chang JS
    J Formos Med Assoc; 2000 Dec; 99(12):902-5. PubMed ID: 11155742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
    Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
    Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
    Lo SC; Chang JS; Lin SW; Lin DT
    Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Red cells, HLA and platelet antibody formation in patients with multiple transfusions.
    Chow MP; Hu HY; Lyou JY; Lin JS; Yung CH; Lee A; Lee TD
    Acta Haematol; 1994; 92(2):57-60. PubMed ID: 7817704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
    Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
    Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA antigen and antibody association in platelet-alloimmunized patients.
    Chow MP; Lin JS; Lin CK; Kuo BI; Yung CH; Lyou JY; Hu HY; Tzeng JL; Lee TD
    Zhonghua Yi Xue Za Zhi (Taipei); 1993 May; 51(5):329-32. PubMed ID: 8334558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients.
    Schnaidt M; Northoff H; Wernet D
    Transfus Med; 1996 Jun; 6(2):111-4. PubMed ID: 8809957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of enzyme treatment to enhance reactivity of HLA and platelet-specific antibodies in solid-phase RBC adherence assays.
    Leach MF; AuBuchon JP
    Transfusion; 2002 Apr; 42(4):476-80. PubMed ID: 12076296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPA antibodies in Algerian multitransfused patients: Prevalence and involvement in platelet refractoriness.
    Brouk H; Bertrand G; Zitouni S; Djenouni A; Martageix C; Griffi F; Kaplan C; Ouelaa H
    Transfus Apher Sci; 2015 Jun; 52(3):295-9. PubMed ID: 25620758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alloantibodies to human platelet glycoprotein antigens (HPA) and HLA class 1 in a cross section of Nigerian antenatal women.
    Jeremiah ZA; Atiegoba AI; Mgbere O
    Hum Antibodies; 2011; 20(3-4):71-5. PubMed ID: 22129676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukoreduced red blood cell transfusions do not induce platelet glycoprotein antibodies in patients with sickle cell disease.
    Nickel RS; Winkler AM; Horan JT; Hendrickson JE
    Transfusion; 2016 Sep; 56(9):2267-73. PubMed ID: 27385599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet alloimmunization after transfusion. A prospective study in 117 heart surgery patients.
    Taaning E; Simonsen AC; Hjelms E; Svejgaard A; Morling N
    Vox Sang; 1997; 72(4):238-41. PubMed ID: 9228715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet immunology. ELISA for detection of platelet antibodies, platelet-specific antigens and platelet glycoproteins.
    Taaning E
    Dan Med Bull; 1992 Aug; 39(4):343-54. PubMed ID: 1382006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders.
    Kurz M; Greinix H; Höcker P; Kalhs P; Knöbl P; Mayr WR; Pober M; Panzer S
    Br J Haematol; 1996 Dec; 95(3):564-9. PubMed ID: 8943903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detection of platelet antibodies by simultaneous analysis of specific platelet antibodies and the monoclonal antibody-specific immobilization of platelet antigens: an interlaboratory comparison.
    Nguyen XD; Goebel M; Schober M; Klüter H; Panzer S
    Transfusion; 2010 Jul; 50(7):1429-34. PubMed ID: 20456677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A platelet monoclonal antibody inhibition assay for detection of glycoprotein IIb/IIIa-related platelet alloantibodies.
    Reiner AP; Teramura G; Nelson KA; Slichter SJ
    J Immunol Methods; 1995 Aug; 184(2):153-62. PubMed ID: 7658019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of immobilized platelet membrane glycoproteins for the detection of platelet-specific alloantibodies in solid-phase ELISA.
    Collins J; Aster RH
    Vox Sang; 1987; 53(3):157-61. PubMed ID: 3318122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.